- Patent Title: Acyl phosphonamidates and acyl benzylamines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
-
Application No.: US16425665Application Date: 2019-05-29
-
Publication No.: US10703745B2Publication Date: 2020-07-07
- Inventor: Anne-Marie Beausoleil , Ryan Hudson
- Applicant: Unity Biotechnology, Inc.
- Applicant Address: US CA South San Francisco
- Assignee: Unity Biotechnology, Inc.
- Current Assignee: Unity Biotechnology, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: Bozicevic, Field & Francis LLP
- Agent Rudy J. Ng
- Main IPC: C07D401/12
- IPC: C07D401/12 ; C07D413/12 ; C07D413/14 ; C07D241/04 ; A61P31/00

Abstract:
This disclosure provides compounds with Bcl inhibitory activity based on a new chemical scaffold. Acyl phosphonamidate compounds may include a P-phenyl phosphonamidate moiety which is N-acylated with an aroyl or heteroaroyl group. The P-phenyl phosphonamidate moiety can be optionally substituted at phosphorus with thio (═S) instead of oxo (═O), and/or with a thioxy group or a second amino group instead of an oxy group. One of the heteroatoms attached to phosphorus can be cyclically linked to a carbon atom of the adjacent phenyl ring attached to the phosphorus to provide, together with the phosphorus atom through which they are connected, a heterocyclic ring. By incorporating such a cyclic constraint between two phosphorus substituents of the core linking moiety a favorable binding conformation can be promoted in the compounds. Selected compounds promote apoptosis in senescent cells, and can be developed for treating senescent-related conditions, such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis. Selected compounds promote apoptosis in cancer cells, and can be developed as chemotherapeutic agents.
Public/Granted literature
Information query